JPMorgan added Scholar Rock (SRRK) to the firm’s Analyst Focus List as a growth idea and also placed the stock on “Positive Catalyst Watch.” JPMorgan remains focused on the potential for apitegromab in spinal muscular atrophy and the company’s execution on regulatory approvals and launches for the drug across key geographies, starting with the U.S. If approved, which is “highly likely” given the positive results from the Phase 3 SAPPHIRE trial in patients with non-ambulatory Type 2/3 spinal muscular atrophy, JPMorgan sees potential for “robust launches,” the analyst tells investors in a research note. The firm keeps an Overweight rating on Scholar Rock with a $46 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
- Buy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results
- Strategic Focus on Neuromuscular Treatments and Promising Study Results Justify Buy Rating for Scholar Rock
- Scholar Rock’s Strategic Shift and Promising Advancements Drive Buy Rating
- Morning Movers: Circle rises following regulatory framework for stablecoins